脑肿瘤的放射免疫疗法
Radioimmunotherapy (RIT) in Brain Tumors.
作者信息
Gholamrezanezhad Ali, Shooli Hossein, Jokar Narges, Nemati Reza, Assadi Majid
机构信息
1Department of Diagnostic Radiology, Keck School of Medicine, University of Southern California (USC), 1520 San Pablo Street, Suite L1600, Los Angeles, CA 90033 USA.
2Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
出版信息
Nucl Med Mol Imaging. 2019 Dec;53(6):374-381. doi: 10.1007/s13139-019-00618-6. Epub 2019 Nov 12.
Annually, the incidence of brain tumors has slightly increased and also the patient prognosis is still disappointing, especially for high-grade neoplasms. So, researchers seek methods to improve therapeutic index as a critical aim of treatment. One of these new challenging methods is radioimmunotherapy (RIT) that involves recruiting a coupling of radionuclide component with monoclonal antibody (mAb) which are targeted against cell surface tumor-related antigens or antigens of cells within the tumor microenvironment. In the context of cancer care, precision medicine is exemplified by RIT; precision medicine can offer a tailored treatment to meet the needs for treatment of brain tumors. This review aims to discuss the molecular targets used in radioimmunotherapy of brain tumors, available and future radioimmunopharmaceutics, clinical trials of radioimmunotherapy in brain neoplasms, and eventually, conclusion and future perspective of application of radioimmunotherapy in neurooncology cancer care.
每年，脑肿瘤的发病率略有上升，而且患者的预后仍然令人失望，尤其是对于高级别肿瘤。因此，研究人员寻求提高治疗指数的方法作为治疗的关键目标。这些具有挑战性的新方法之一是放射免疫疗法（RIT），它涉及将放射性核素成分与单克隆抗体（mAb）偶联，这些单克隆抗体靶向细胞表面肿瘤相关抗原或肿瘤微环境内细胞的抗原。在癌症治疗方面，放射免疫疗法体现了精准医学；精准医学可以提供量身定制的治疗方案，以满足脑肿瘤的治疗需求。本综述旨在讨论脑肿瘤放射免疫治疗中使用的分子靶点、现有的和未来的放射免疫药物、脑肿瘤放射免疫治疗的临床试验，以及最终放射免疫治疗在神经肿瘤癌症治疗中的应用结论和未来展望。
Zotero 插件